Inari Medical

Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in July 2011 and is headquartered in Irvine, CA.

Earnings data Q1 2020

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inari Medical reports robust Q4 earnings and eyes international expansion

Inari Medical's Q4 2022 earnings call highlighted strong revenue growth, operational challenges, and strategic opportunities for market expansion and product innovation.
The company's focus on patient outcomes, superior product performance, and international growth positions it for continued success in 2023 and beyond.
Efforts to optimize gross margins, manage operating expenses, and drive market adoption present key areas for Inari's future financial performance and profitability.
With a clear revenue guidance for 2023 and a commitment to sustained operating profitability, Inari Medical demonstrates a strategic roadmap for sustainable growth.

Inari Medical reports robust Q1 earnings, eyes sustained profitability

Inari Medical's Q1 earnings call highlighted strong financial performance, growth strategies, and product innovations. Challenges include competitive dynamics and assessing seasonality trends. The company is well-positioned for sustained growth and market expansion.

Inari Medical reports record revenue and eyes Asian market expansion

Inari Medical's Q2 2023 performance reflects robust financial growth, international expansion, and a strategic focus on addressing unmet needs in the CVD market.
With a strong product portfolio, sustained profitability, and market development initiatives, Inari Medical is well-equipped to capitalize on growth opportunities and drive innovation.
Challenges in market entry, product redesign timelines, and regulatory approvals are being navigated as the company aims for sustained growth and market leadership in the medical device sector.

Inari Medical reports robust Q3 earnings, acquires LimFlow for growth

Inari Medical's Q3 performance reflects strong financial growth, operational improvements, and strategic acquisitions driving future prospects.
While challenges like declining margins and delayed profit targets exist, opportunities in new markets, product pricing, and synergies offer avenues for sustained growth.
The LimFlow acquisition positions Inari well in the CLTI market, with a focus on revenue growth, operational efficiency, and market expansion.
Overall, Inari's confidence in its core business and strategic moves like the LimFlow acquisition signal a positive trajectory and growth outlook.

Inari Medical reports record revenue, eyes sustained profitability amid challenges

Inari Medical's Q4 2023 performance showcased strong revenue growth, operational progress, and a strategic focus on market leadership and patient care.
While facing challenges such as regulatory scrutiny and increased operating expenses, the company remains optimistic about revenue growth and sustained profitability.
Opportunities lie in diversified revenue streams, international expansion, and product portfolio enhancements, positioning Inari for continued growth and market leadership.
Overall, Inari Medical's strategic initiatives and financial performance indicate a resilient and growth-oriented trajectory in the medical device industry.

Inari Medical reports record Q1 revenue, raises full-year guidance

Inari Medical's Q1 performance reflects robust revenue growth, strategic investments, and international expansion, positioning the company for sustained profitability and market leadership.
While facing challenges in competition and market dynamics, Inari's strengths in innovation, global performance, and product development offer avenues for growth and differentiation.
The company's focus on operational efficiency, strategic investments, and product enhancements align with opportunities in expanding toolkits, new therapies, and market presence.

Inari Medical reports record revenue, eyes sustained profitability and global expansion

Inari Medical's Q2 2024 performance reflects strong revenue growth but with operating losses, signaling a need for cost management strategies.
The company's strategic strengths lie in sustained profitability projections, successful business integrations, and expansion into key international markets.
Challenges include leadership transition risks, operational hurdles in new markets, and the need to meet high market expectations with upcoming data releases.
Opportunities for Inari include optimizing costs, leveraging growth in China and Japan, capitalizing on new product adoption, and driving further market expansion.

Inari Medical reports record revenue and eyes global expansion

Inari Medical's Q3 performance reflects robust revenue growth and strategic focus on expanding therapies globally.
The company's strengths lie in revised revenue guidance, upcoming profitability, and promising study outcomes.
Challenges include managing expenses, reducing losses, and sustaining high margins amidst market competition.
Opportunities abound in driving growth, capitalizing on new therapies, and expanding market presence internationally.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in June 2011 and is headquartered in Irvine, CA.

Inari Medical's (NARI) first-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the companies continue to incur operating losses.

Inari Medical (NARI) Q1 Earnings Miss Estimates, OpEx Rises

Inari Medical, Inc. (NASDAQ:NARI ) Q1 2024 Earnings Conference Call April 30, 2024 4:30 PM ET Company Participants John Hsu - Vice President, Investor Relations Drew Hykes - Chief Executive Officer Mitch Hill - Chief Financial Officer Tom Tu - Chief Medical Officer Conference Call Participants Stephanie Piazzola - Bank of America Marie Thibault - BTIG Kallum Titchmarsh - Morgan Stanley William Plovanic - Canaccord Chris Pasquale - Nephron Research David Rescott - Baird Michael Sarcone - Jefferies Adam Maeder - Piper Sandler Richard Newitter - Truist Securities Operator Good day, ladies and gentlemen. And welcome to Inari Medical Inc. First Quarter 2024 Earnings Conference Call.

Inari Medical, Inc. (NARI) Q1 2024 Earnings Call Transcript

Inari Medical, Inc. (NARI) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.04 per share a year ago.

Inari Medical, Inc. (NARI) Reports Q1 Loss, Tops Revenue Estimates

IRVINE, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its first quarter ended March 31, 2024.

Inari Medical Reports First Quarter 2024 Financial Results

NEW YORK, NY / ACCESSWIRE / April 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Inari Medical, Inc. ("Inari Medical, Inc.") (NASDAQ:NARI) concerning possible violations of federal securities laws. On February 28, 2024, after the market close, Inari Medical announced Q4 and full-year 2023 financial results and disclosed receipt of a civil investigative demand from the US Department of Justice under the federal Anti-Kickback Statute and Civil False Claims Act over certain payments to healthcare professionals.

Lost Money on Inari Medical, Inc.(NARI)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

LOS ANGELES, CA / ACCESSWIRE / April 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Inari Medical, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK, NY / ACCESSWIRE / April 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Inari Medical, Inc. ("Inari Medical, Inc.") (NASDAQ:NARI) concerning possible violations of federal securities laws. On February 28, 2024, after the market close, Inari Medical announced Q4 and full-year 2023 financial results and disclosed receipt of a civil investigative demand from the US Department of Justice under the federal Anti-Kickback Statute and Civil False Claims Act over certain payments to healthcare professionals.

Did Inari Medical, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - NARI

Inari Medical, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - NARI

Inari Medical, Inc. (NARI) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates

IRVINE, Calif., April 17, 2024 (GLOBE NEWSWIRE) --  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its first quarter 2024 financial results on Tuesday, April 30, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Inari Medical to Announce First Quarter 2024 Financial Results

NEW YORK, NY / ACCESSWIRE / April 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Inari Medical, Inc. ("Inari Medical, Inc.") (NASDAQ:NARI) concerning possible violations of federal securities laws. On February 28, 2024, after the market close, Inari Medical announced Q4 and full-year 2023 financial results and disclosed receipt of a civil investigative demand from the US Department of Justice under the federal Anti-Kickback Statute and Civil False Claims Act over certain payments to healthcare professionals.

Lost Money on Inari Medical, Inc.(NARI)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / April 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Inari Medical, Inc. ("Inari Medical, Inc.") (NASDAQ:NARI) concerning possible violations of federal securities laws. On February 28, 2024, after the market close, Inari Medical announced Q4 and full-year 2023 financial results and disclosed receipt of a civil investigative demand from the US Department of Justice under the federal Anti-Kickback Statute and Civil False Claims Act over certain payments to healthcare professionals.

An Investigation Has Commenced on Behalf of Inari Medical, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your NARI Losses

IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the publication of its 2023 Ethos and Sustainability Report. The report highlights Inari's commitment to its ethos and important corresponding environmental, social and governance (ESG) initiatives. The report can be found on Inari's website here.

Inari Medical Announces the Release of 2023 Ethos and Sustainability Report

ATTENTION NARI SHAREHOLDERS: Investors who Lost Money on Inari Medical, Inc. are Urged to Contact Levi & Korsinsky about an Ongoing Investigation

NEW YORK, NY / ACCESSWIRE / April 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Inari Medical, Inc. ("Inari Medical, Inc.") (NASDAQ:NARI) concerning possible violations of federal securities laws. On February 28, 2024, after the market close, Inari Medical announced Q4 and full-year 2023 financial results and disclosed receipt of a civil investigative demand from the US Department of Justice under the federal Anti-Kickback Statute and Civil False Claims Act over certain payments to healthcare professionals.

NARI ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Inari Medical, Inc. investment

Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.

Why You Should Retain Inari Medical (NARI) Stock for Now

NEW YORK, NY / ACCESSWIRE / April 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Inari Medical, Inc. ("Inari Medical, Inc.") (NASDAQ:NARI) concerning possible violations of federal securities laws. On February 28, 2024, after the market close, Inari Medical announced Q4 and full-year 2023 financial results and disclosed receipt of a civil investigative demand from the US Department of Justice under the federal Anti-Kickback Statute and Civil False Claims Act over certain payments to healthcare professionals.

Levi & Korsinsky Reminds Shareholders of an Investigation into Inari Medical, Inc. (NARI) Regarding Potential Securities Fraud Allegations

LOS ANGELES, CA / ACCESSWIRE / April 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Inari Medical, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK, NY / ACCESSWIRE / April 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Inari Medical, Inc. ("Inari Medical, Inc.") (NASDAQ:NARI) concerning possible violations of federal securities laws. On February 28, 2024, after the market close, Inari Medical announced Q4 and full-year 2023 financial results and disclosed receipt of a civil investigative demand from the US Department of Justice under the federal Anti-Kickback Statute and Civil False Claims Act over certain payments to healthcare professionals.

NARI ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Inari Medical, Inc. Shareholders Who Lost Money

LOS ANGELES, CA / ACCESSWIRE / April 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Inari Medical, Inc. and Encourages Investors with Losses to Contact the Firm

IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), today announced the appointment of Tim Benner as Senior Vice President of U.S. Sales and Dr. Andrew Niekamp as Vice President of Medical Affairs. Mr. Benner will be responsible for developing effective strategies across the company's multi-product sales platform and leading a high-performance commercial team to drive therapy penetration. Dr. Niekamp will be instrumental in advancing Inari's mission to improve patient care through physician education and new device development.

Inari Medical Strengthens Senior Leadership Team with Addition of Two Executives

LOS ANGELES, CA / ACCESSWIRE / April 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Inari Medical, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK, NY / ACCESSWIRE / April 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Inari Medical, Inc. ("Inari Medical, Inc.") (NASDAQ:NARI) concerning possible violations of federal securities laws. On February 28, 2024, after the market close, Inari Medical announced Q4 and full-year 2023 financial results and disclosed receipt of a civil investigative demand from the US Department of Justice under the federal Anti-Kickback Statute and Civil False Claims Act over certain payments to healthcare professionals.

Inari Medical, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Inari Medical, Inc. (NARI)

Inari Medical (NARI) reported earnings 30 days ago. What's next for the stock?

Inari Medical (NARI) Up 4% Since Last Earnings Report: Can It Continue?

NEW YORK, NY / ACCESSWIRE / March 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Inari Medical, Inc. ("Inari Medical, Inc.") (NASDAQ:NARI) concerning possible violations of federal securities laws. On February 28, 2024, after the market close, Inari Medical announced Q4 and full-year 2023 financial results and disclosed receipt of a civil investigative demand from the US Department of Justice under the federal Anti-Kickback Statute and Civil False Claims Act over certain payments to healthcare professionals.

News for Inari Medical Stock (NARI)